Equities Analysts Offer Predictions for KALV FY2027 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Research analysts at HC Wainwright boosted their FY2027 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Thursday, March 12th. HC Wainwright analyst A. Fein now expects that the specialty pharmaceutical company will post earnings of $0.84 per share for the year, up from their prior forecast of $0.82. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

A number of other equities analysts have also weighed in on KALV. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Needham & Company LLC boosted their price target on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

KalVista Pharmaceuticals Stock Down 2.5%

Shares of NASDAQ:KALV opened at $16.94 on Friday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals has a 52-week low of $9.23 and a 52-week high of $19.00. The business’s 50 day simple moving average is $15.76 and its two-hundred day simple moving average is $14.28. The firm has a market cap of $856.32 million, a P/E ratio of -4.29 and a beta of -0.35.

Insider Buying and Selling

In related news, insider Nicole Sweeny sold 3,975 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the completion of the sale, the insider directly owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. This represents a 7.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,693 shares of KalVista Pharmaceuticals stock in a transaction on Monday, March 9th. The stock was sold at an average price of $16.08, for a total transaction of $107,623.44. Following the transaction, the chief executive officer directly owned 451,815 shares in the company, valued at $7,265,185.20. This represents a 1.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 33,378 shares of company stock worth $522,290. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Tudor Investment Corp ET AL bought a new position in KalVista Pharmaceuticals during the third quarter worth about $24,360,000. Vestal Point Capital LP lifted its stake in shares of KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares in the last quarter. Parkman Healthcare Partners LLC lifted its stake in shares of KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after buying an additional 1,055,940 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after buying an additional 905,053 shares during the period. Finally, Elmind Capital LP bought a new position in KalVista Pharmaceuticals in the 4th quarter worth approximately $12,941,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.